


Xeticam™

[Levetiracetam]

250mg, 500mg & 750mg Film coated Tablets

DESCRIPTION

Xeticam (Levetiracetam) is an analogue of piracetam. The chemical name of levetiracetam, a single enantiomer, is (-)-(-S)- α -ethyl-2-oxo-1-pyrrolidineacetamide. Its molecular formula is $C_8H_{14}N_2O_2$ and the structural formula is:



QUALITATIVE AND QUANTITATIVE COMPOSITION

Xeticam (Levetiracetam) is available for oral administration as:

- 1) Xeticam Tablets 250mg
Each film-coated tablet contains:
Levetiracetam USP...250mg
- 2) Xeticam Tablets 500mg
Each film-coated tablet contains:
Levetiracetam USP...500mg
- 3) Xeticam Tablets 750mg
Each film-coated tablet contains:
Levetiracetam USP...750mg

CLINICAL PHARMACOLOGY

Mechanism of Action

The mechanism of action of levetiracetam still remains to be fully elucidated. In vitro studies show that levetiracetam affects intraneuronal Ca^{2+} levels by partial inhibition of N-type Ca^{2+} currents and by reducing the release of Ca^{2+} from intraneuronal stores. In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β -carbolines. Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. This binding site is the synaptic vesicle protein 2A, believed to be involved in vesicle fusion and neurotransmitter exocytosis. Levetiracetam and related analogs show a rank order of affinity for binding to the synaptic vesicle protein 2A which correlates with the potency of their anti-seizure protection in the mouse audiogenic model of epilepsy. This finding suggests that the interaction between levetiracetam and the synaptic vesicle protein 2A seems to contribute to the antiepileptic mechanism of action of the medicinal product.

Pharmacokinetics

Adults and adolescents

Absorption

Levetiracetam is rapidly absorbed after oral administration. Oral absolute bioavailability is close to 100%. Peak plasma concentrations (C_{max}) are achieved at 1.3 hours after dosing. Steady-state is achieved after two days of a twice daily administration schedule. Peak concentrations (C_{max}) are typically 31 and 43 μ g/ml following a single 1000mg dose and repeated 1000mg twice daily dose, respectively. The pharmacokinetics of levetiracetam are linear over the dose range of 500mg - 5000mg.

Effect of Food

Food does not affect the extent of absorption of levetiracetam but it decreases C_{max} by 20% and delays T_{max} by 1.5 hours. The extent of absorption is dose-independent and is not altered by food.

Distribution

No tissue distribution data are available in humans. Neither levetiracetam nor its primary metabolite are significantly bound to plasma proteins (< 10%). The volume of distribution of levetiracetam is approximately 0.5 to 0.7 l/kg, a value close to the total body water volume.

Metabolism

Levetiracetam is not extensively metabolized in humans. The major metabolic pathway (24% of the dose) is an enzymatic hydrolysis of the acetamide group. Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. Hydrolysis of the acetamide group was measurable in a large number of tissues including blood cells. The metabolite ucb L057 is pharmacologically inactive. Two minor metabolites were also identified. One was obtained by hydroxylation of the pyrrolidone ring (1.6% of the dose) and the other one by opening of the pyrrolidone ring (0.9% of the dose). No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite.

Elimination

Levetiracetam plasma half-life in adults is 7 ± 1 hour and is unaffected by either dose or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as unchanged drug which represents 66% of administered dose. The total body clearance is 0.96mL/min/kg and the renal clearance is 0.6mL/min/kg. The mechanism of excretion is glomerular filtration with subsequent partial tubular reabsorption. The metabolite ucb L057 is excreted by glomerular filtration and active tubular secretion with a renal clearance of 4mL/min/kg. Levetiracetam elimination is correlated to creatinine clearance. Levetiracetam clearance is reduced in patients with renal impairment.

Special Population

Elderly

In the elderly, the half-life is increased by about 40% (10 to 11 hours). This is related to the decrease in renal function in this population.

Renal impairment

The disposition of levetiracetam was studied in adult subjects with varying degrees of renal function. Total body clearance of levetiracetam is reduced in patients with impaired renal function by 40% in the mild group ($CL_{cr} = 50-80$ mL/min), 50% in the moderate group ($CL_{cr} = 30-50$ mL/min) and 60% in the severe renal impairment group ($CL_{cr} < 30$ mL/min). Clearance of levetiracetam is correlated with creatinine clearance. In anuric (end stage renal disease) patients, the total body clearance decreased 70% compared to normal subjects ($CL_{cr} > 80$ mL/min). Approximately 50% of the pool of

levetiracetam in the body is removed during a standard 4- hour hemodialysis procedure.

Hepatic impairment

In subjects with mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of levetiracetam were unchanged. In patients with severe hepatic impairment (Child-Pugh C), total body clearance was 50% that of normal subjects, but decreased renal clearance accounted for most of the decrease. No dose adjustment is needed for patients with hepatic impairment.

Pediatric population

Children (6 to 12 years)

Following single oral dose administration (20mg/kg) to epileptic children (6 to 12 years), the half-life of levetiracetam was 6 hours. The apparent body weight adjusted clearance was approximately 30% higher than in epileptic adults. Following repeated oral dose administration (20 to 60mg/kg/day) to epileptic children (4 to 12 years), levetiracetam was rapidly absorbed. Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. Linear and dose proportional increases were observed for peak plasma concentration and area under the curve. The elimination half-life was approximately 5 hours. The apparent body clearance was 1.1mL/min/kg.

Gender

Levetiracetam C_{max} and AUC were 20% higher in women (N=11) compared to men (N=12). However, clearances adjusted for body weight were comparable.

THERAPEUTIC INDICATIONS

Xeticam (Levetiracetam) Tablet is indicated as:

Monotherapy:

- in the treatment of partial onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy.

Adjunctive Therapy:

- in the treatment of partial onset seizures with or without secondary generalization in adults, adolescents and children 6 years of age or above with epilepsy.
- in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.
- in the treatment of primary generalized tonic-clonic seizures in adults and adolescents from 6 years of age with Idiopathic Generalized Epilepsy.

DOSAGE & ADMINISTRATION

Xeticam (Levetiracetam) is given with or without food. The dosage regimens depends on the indication, age group, dosage form & renal function. The tablets should be swallowed whole and not be chewed or crushed.

Monotherapy for adults and adolescents from 16 years of age.

The recommended starting dose is 250mg twice daily which should be increased to an initial therapeutic dose of 500mg twice daily after two weeks. The dose can be further increased by 250mg twice daily every two weeks depending upon the clinical response. The maximum dose is 1500mg twice daily.

Dosing for Partial Onset Seizures

Adults 16 Years and Older

Initiate treatment with a daily dose of 1000mg/day, given as twice-daily dosing (500mg twice daily). Additional dosing increments may be given (100mg/day additional every 2 weeks) to a maximum recommended daily dose of 3000mg. There is no evidence that doses greater than 3000mg/day confer additional benefit.

Pediatric Patients (6 Years to < 16 Years)

Initiate treatment with a daily dose of 20mg/kg in 2 divided doses (10mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20mg/kg to the recommended daily dose of 60mg/kg (30mg/kg twice daily). If a patient cannot tolerate a daily dose of 60mg/kg, the daily dose may be reduced. In the clinical trial, the mean daily dose was 44mg/kg. The maximum daily dose was 3000mg/day.

For Xeticam (Levetiracetam) Tablet, dosing in pediatric patients weighing 20kg to 40kg, initiate treatment with a daily dose of 500mg given as twice daily dosing (250mg twice daily). Increase the daily dose every 2 weeks by increments of 500mg to a maximum recommended daily dose of 1500mg (750mg twice daily).

For Xeticam (Levetiracetam) Tablet, dosing in pediatric patients weighing more than 40kg, initiate treatment with a daily dose of 1000mg/day given as twice daily dosing (500mg twice daily). Increase the daily dose every 2 weeks by increments of 1000mg/day to a maximum recommended daily dose of 3000mg (1500mg twice daily).

Dosing for Myoclonic Seizures in Patients 12 Years of Age and Older with Juvenile Myoclonic Epilepsy

Initiate treatment with a dose of 1000mg/day, given as twice-daily dosing (500mg twice daily). Increase the dosage by 1000mg/day every 2 weeks to the recommended daily dose of 3000mg. The effectiveness of doses lower than 3000mg/day has not been studied.

Dosing for Primary Generalized Tonic-Clonic Seizures

Adults 16 Years and Older

Initiate treatment with a dose of 1000mg/day, given as twice-daily dosing (500mg twice daily). Increase dosage by 1000mg/day every 2 weeks to the recommended daily dose of 3000mg. The effectiveness of doses lower than 3000mg/day has not been adequately studied.

Pediatric Patients (Ages 6 to <16 Years)

Initiate treatment with a daily dose of 20mg/kg in 2 divided doses (10mg/kg twice daily). Increase the daily dose every 2 weeks by increments of 20mg/kg to the recommended daily dose of 60mg/kg (30mg/kg twice daily). The effectiveness of doses lower than 60mg/kg/day has not been adequately studied.

Discontinuation

If Xeticam (Levetiracetam) has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50kg: 500mg decreases twice daily every two to four weeks; in children and adolescents weighting less than 50kg: dose decrease should not exceed 10mg/kg twice daily every two weeks).

Special populations

Elderly (65 years and older)

Adjustment of the dose is recommended in elderly patients with compromised renal function.

زیٹی کیم

Renal impairment

The daily dose must be individualized according to renal function. For adult patients, refer to the following table and adjust the dose as indicated.

Dosing adjustment for adult and adolescents patients with impaired renal function.

Group	Creatinine Clearance (ml/min/1.73m ²)	Dosage and frequency
Normal	> 80	500mg to 1500mg twice daily
Mild	50-79	500mg to 1000mg twice daily
Moderate	30-49	250mg to 750mg twice daily
Severe	< 30	250mg to 500mg twice daily
End-stage renal disease patients undergoing dialysis ⁽¹⁾	-	500mg to 1000mg once daily ⁽²⁾

⁽¹⁾ A 750mg loading dose is recommended on the first day of treatment with levetiracetam.

⁽²⁾ Following dialysis, a 250mg to 500mg supplemental dose is recommended.

For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function.

Dosing adjustment for children and adolescents patients weighing less than 50kg with impaired renal function.

Group	Creatinine Clearance (ml/min/1.73m ²)	Dosage and frequency
Normal	> 80	10 to 30mg/kg twice daily
Mild	50-79	10 to 20mg/kg twice daily
Moderate	30-49	5 to 15mg/kg twice daily
Severe	< 30	5 to 10mg/kg twice daily
End-stage renal disease patients undergoing dialysis	-	10 to 20mg/kg once daily ⁽¹⁾⁽²⁾

⁽¹⁾ Following dialysis, a 3.5 to 7mg/kg supplemental dose is recommended.

⁽²⁾ Following dialysis, a 5 to 10mg/kg supplemental dose is recommended.

Hepatic impairment

No dose adjustment is needed in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the creatinine clearance may underestimate the renal insufficiency. Therefore a 50% reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60ml/min/1.73m².

Paediatric population

Monotherapy

The safety & efficacy of levetiracetam in children and adolescents below 16 years as monotherapy treatment have not been established.

Add-on therapy for children (6 to 11 years) and adolescents (12 to 17 years) weighing less than 50kg

The lowest effective dose should be used. The starting dose for a child or adolescent of 25kg should be 250mg twice daily with a maximum dose of 750mg twice daily. Dose in children 50kg or greater is the same as in adults.

ADVERSE REACTIONS

Very common: Nasopharyngitis, somnolence and headache.

Common: Anorexia, depression, hostility/aggression, anxiety, insomnia, nervousness/irritability, convulsion, balance disorder, dizziness, lethargy, tremor, vertigo, cough, abdominal pain, diarrhoea, dyspepsia, vomiting, nausea, rash and asthenia/fatigue.

Uncommon: Thrombocytopenia, leucopenia, weight decrease, weight increase, suicide attempt and suicidal ideation, psychotic disorder, abnormal behaviour, hallucination, anger, confusional state, panic attack, emotional instability/mood swings, agitation, amnesia, memory impairment, abnormal coordination/ataxia, paraesthesia, disturbance in attention, diplopia, vision blurred, liver function test abnormal, alopecia, eczema, pruritus, muscle weakness, myalgia and injury.

Rare: Infection, pancytopenia, neutropenia, agranulocytopenia, drug reaction with eosinophilia and systemic symptoms (DRESS), hypersensitivity, hyponatraemia, completed suicide, personality disorder, thinking abnormal, hepatic failure, hepatitis, acute kidney injury, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, rhabdomyolysis and blood creatine phosphokinase increased.

"To report SUSPECTED ADVERSE REACTIONS to Getz Pharma's Pharmacovigilance Section, please contact at dsafety@getzpharma.com or +92-21-38636363"

CONTRAINDICATIONS

Levetiracetam is contraindicated in patients who are hypersensitive to the active substance or other pyrrolidone derivatives or to any excipient of the product.

PRECAUTIONS

Renal impairment

The administration of levetiracetam to patients with renal impairment may require dose adjustment. In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection.

Acute kidney injury

The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months.

Blood cell counts

Rare cases of decreased blood cell counts (neutropenia, agranulocytosis, leucopenia, thrombocytopenia and pancytopenia) have been described in association with levetiracetam administration, generally at the beginning of the treatment. Complete blood cell counts are advised in patients experiencing significant weakness, pyrexia, recurrent infections or coagulation disorders.

Suicide

Antiepileptic drugs (AEDs), including levetiracetam, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Anaphylaxis and Angioedema

Levetiracetam can cause anaphylaxis or angioedema after the first dose or at any time during treatment. If a patient develops signs or symptoms of anaphylaxis or angioedema, levetiracetam should be discontinued and the patient should seek immediate medical attention. Levetiracetam should be discontinued permanently if a clear alternative etiology for the reaction cannot be established.

Serious Dermatological Reactions

Serious dermatological reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in both pediatric and adult patients treated with levetiracetam. The median time of onset is reported to be 14 to 17 days, but cases have been reported at least four months after initiation of treatment. Recurrence of the serious skin reactions following rechallenge with levetiracetam has also been reported. Levetiracetam should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed and alternative therapy should be considered.

Withdrawal Seizures

Antiepileptic drugs, including levetiracetam, should be withdrawn gradually to minimize the potential of increased seizure frequency.

Somnolence and Fatigue

Levetiracetam may cause somnolence, fatigue, coordination difficulties. Patients should be monitored for these signs and symptoms and advised not to drive or operate machinery until they have gained sufficient experience on levetiracetam to gauge whether it adversely affects their ability to drive or operate machinery.

Seizure Control During Pregnancy

Physiological changes may gradually decrease plasma levels of levetiracetam throughout pregnancy. This decrease is more pronounced during the third trimester. It is recommended that patients be monitored carefully during pregnancy. Close monitoring should continue through the postpartum period especially if the dose was changed during pregnancy.

Pregnancy

There are no adequate and controlled studies in pregnant women. In animal studies, levetiracetam produced evidence of developmental toxicity, including teratogenic effects, at doses similar to or greater than human therapeutic doses. Levetiracetam should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Levetiracetam is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from levetiracetam, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

DRUG INTERACTIONS

Probenecid

Renal clearance of ucb L057 in the presence of probenecid decreased 60%, probably related to competitive inhibition of tubular secretion of ucb.

Methotrexate

Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs.

Laxatives

There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. Therefore, macrogol should not be taken orally for one hour before and for one hour after taking levetiracetam.

OVERDOSAGE:

The highest known dose of levetiracetam received in the clinical development program was 6000mg/day. Other than drowsiness, there were no adverse reactions in the few known cases of overdose in clinical trials. Somnolence, agitation, aggression, depressed level of consciousness, respiratory depression and coma were observed with levetiracetam overdoses in post-marketing use.

Management of overdose

There is no specific antidote for overdose with levetiracetam. If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavage; usual precautions should be observed to maintain airway. General supportive care of the patient is indicated including monitoring of vital signs and observation of the patient's clinical status.

STORAGE

Do not store above 30°C.
Protect from light and moisture.
The expiry date refers to the product correctly stored at the required conditions.

HOW SUPPLIED

Xeticam (Levetiracetam) Tablets 250mg are available in blister pack of 10's.
Xeticam (Levetiracetam) Tablets 500mg are available in blister pack of 10's.
Xeticam (Levetiracetam) Tablets 750mg are available in blister pack of 10's.

Keep out of reach of children.

To be sold on prescription of a registered medical practitioner only.

Please read the contents carefully before use.
This package insert is continually updated from time to time.

Manufactured by:

 **Getz**
pharma
(PVT) LIMITED
www.getzpharma.com | 29-30/27,
K.I.A., Karachi,
Pakistan

L-200010907